Table of Content

1. EXECUTIVE SUMMARY

2. INTRODUCTION
2.1. Overview of Antibiotics
2.2. Characteristics of an Ideal Antibiotic
2.3. Advantages of Antibiotics
2.4. Classification of Antibiotics
2.5. History of Antibiotics
2.6. Innovations in Antibiotics
2.7. Mechanism of Action of Antibiotics
2.8. Challenges associated with the use of Antibiotics
2.9. Future Perspectives

3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS
3.1. Approved Antibiotic Generics: Overall Market Landscape
3.1.1. Analysis by Year of Approval
3.1.2. Analysis by Region(s) of Approval
3.1.4. Analysis by Type of Antibiotic (based on Chemical Structure)
3.1.3. Analysis by Type of Antibiotic (based on Drug Class)
3.1.5. Analysis by Mechanism of Action
3.1.6. Analysis by Spectrum of Activity
3.1.7. Analysis by Type of Target Bacteria(s)
3.1.8. Analysis by Target Bacterial Strain(s)
3.1.9. Analysis by Target Disease Indication(s)
3.1.10. Analysis by Nature of Source
3.1.11. Analysis by Type of Therapy
3.1.12. Analysis by Route(s) of Administration
3.1.13. Analysis by Dosage Form(s)
3.1.14. Analysis by Type of Patient Population (based on Age)
3.1.15. Analysis by Type of Patient Population (based on Gender)
3.2. Approved Antibiotic Generics: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Analysis by Location of Headquarters
3.2.4. Most Active Players: Analysis by Number of Approved Generics

4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS
4.1. Approved Antibiotic Brands: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Region(s) of Approval
4.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
4.1.4. Analysis by Type of Antibiotic (based on Drug Class)
4.1.5. Analysis by Mechanism of Action
4.1.6. Analysis by Spectrum of Activity
4.1.7. Analysis by Type of Target Bacteria
4.1.8. Analysis by Target Bacterial Strain(s)
4.1.9. Analysis by Target Disease Indication(s)
4.1.10. Analysis by Nature of Source
4.1.11. Analysis by Type of Therapy
4.1.12. Analysis by Route(s) of Administration
4.1.13. Analysis by Dosage Form(s)
4.1.14. Analysis by Type of Patient Population (based on Age)
4.1.15. Analysis by Type of Patient Population (based on Gender)
4.1.16. Analysis by Type of Innovation
4.2. Approved Antibiotic Brands: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.4. Analysis by Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Approved Brands

5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS
5.1. Clinical -Stage Antibiotics: Overall Market Landscape
5.1.1. Analysis by Status of Development
5.1.2. Analysis by Stage of Development
5.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
5.1.4. Analysis by Type of Antibiotic (based on Drug Class)
5.1.5. Analysis by Mechanism of Action
5.1.6. Analysis by Spectrum of Activity
5.1.7. Analysis by Type of Target Bacteria(s)
5.1.8. Analysis by Target Bacterial Strain(s)
5.1.9. Analysis by Target Disease Indication(s)
5.1.10. Analysis by Therapeutic Area(s)
5.1.11. Analysis by Nature of Source
5.1.12. Analysis by Type of Therapy
5.1.13. Analysis by Route(s) of Administration
5.1.14. Analysis by Dosage Form(s)
5.1.15. Analysis by Dosage Strength
5.1.16. Analysis by Dosage Frequency
5.1.17. Analysis by Dosing Period
5.1.18. Analysis by Type of Patient Population (based on Age)
5.1.19. Analysis by Type of Patient Population (based on Gender)
5.1.20. Analysis by Special Designation Received
5.2. Clinical -Stage Antibiotics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Most Active Players: Analysis by Number of Clinical-stage Antibiotics
5.2.5. Most Active Players: Analysis by Number of Preclinical-stage Antibiotics

6. COMPANY PROFILES
6.1. Bristol-Myers Squibb
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments
6.1.6. Key Strategies
6.1.7. Key Focus Areas
6.1.8. Expert Opinion
6.2. Daiichi Sankyo
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments
6.2.6. Key Strategies
6.2.7. Key Focus Areas
6.2.8. Expert Opinion
6.3. GlaxoSmithKline
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments
6.3.6. Key Strategies
6.3.7. Key Focus Areas
6.3.8. Expert Opinion
6.4. Melinta Therapeutics
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Financial Information
6.4.4. Product Portfolio
6.4.5. Recent Developments
6.4.6. Key Strategies
6.4.7. Key Focus Areas
6.4.8. Expert Opinion
6.5. Merck
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments
6.5.6. Key Strategies
6.5.7. Key Focus Areas
6.5.8. Expert Opinion
6.6. Pfizer
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments
6.6.6. Key Strategies
6.6.7. Key Focus Areas
6.6.8. Expert Opinion
6.7. Concluding Remarks

7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS
7.1. Partnership Models
7.2. Antibiotics: List of Partnerships and Collaborations
7.2.1. Analysis by Year of Partnership
7.2.2. Analysis by Type of Partnership
7.2.3. Analysis by Type of Partner
7.2.4. Analysis by Company Size
7.2.5. Local and International Agreements
7.2.6. Intracontinental and Intercontinental Agreements
7.2.7. Most Active Players: Analysis by Number of Partnerships
7.2.8. Concluding Remarks

8. CLINICAL TRIAL ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Antibiotics: Clinical Trial Analysis
8.2.1. Analysis by Trial Registration Year
8.2.2. Analysis by Trial Status
8.2.3. Analysis by Trial Phase
8.2.4. Analysis by Type of Patient Population (based on Gender)
8.2.5 Word Cloud Analysis: Key Focus Areas
8.2.6. Analysis by Type of Sponsor
8.2.7. Analysis by Geography
8.2.8. Most Active Industry Players: Analysis by Number of Trials
8.2.9. Most Active Non-Industry Players: Analysis by Number of Trials

9. KEY OPINION LEADERS
9.1. Assumptions and Key Parameters
9.2. Methodology
9.3. Antibiotics: Key Opinion Leaders (KOLs)
9.3.1. Analysis by Type of KOL
9.3.2. Analysis by Qualification
9.3.3. Analysis by Type of Organization
9.3.4. Analysis by Affiliated Organization
9.3.5. Analysis by Geographical Location of KOLs
9.3.6. Analysis by Target Disease Indication(s)
9.3.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
9.3.8 Most Prominent KOLs: Peer Group 2 (Other Types of Investigators)
9.3.9. Most Prominent KOLs: Analysis by RA score
9.3.10. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.3.11. Concluding Remarks
10. KEY TRENDS IN ANTIBIOTICS INDUSTRY
10.1. Antibiotics Industry: Drug-Pricing Analysis
10.2. Antibiotics Industry: Outsourcing Trends
10.3. Antibiotics Industry: Impact of COVID-19
11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.3. Success Protocol Analysis of Recently Approved Antibiotic Brands
11.3.1. Dovprela (TB Alliance)
11.3.1.1. Drug Overview
11.3.1.2. Success Protocol Analysis
11.3.2. Fetroja (Shionogi)
11.3.2.1. Drug Overview
11.3.2.2. Success Protocol Analysis
11.3.4. Kimyrsa (Melinta Therapeutics)
11.3.4.1. Drug Overview
11.3.4.2. Success Protocol Analysis
11.3.5 Recarbrio (Merck)
11.3.5.1. Drug Overview
11.3.5.2. Success Protocol Analysis
11.3.6. Quofenix (Menarini)
11.3.6.1. Drug Overview
11.3.6.2. Success Protocol Analysis
11.3.9 Xenleta (Nabriva Therapeutics)
11.3.9.1. Drug Overview
11.3.9.2. Success Protocol Analysis
11.4. Concluding Remarks
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Antibiotics Market, 2023-2035
12.3.1. Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2035
12.3.1.1. Antibiotics Market for Aminoglycosides, 2023-2035
12.3.1.2. Antibiotics Market for Cephalosporins, 2023-2035
12.3.1.3. Antibiotics Market for Fluoroquinolones, 2023-2035
12.3.1.4. Antibiotics Market for Macrolides, 2023-2035
12.3.1.5. Antibiotics Market for Oxazolidinones, 2023-2035
12.3.1.6. Antibiotics Market for Penicillins, 2023-2035
12.3.1.7. Antibiotics Market for Sulphonamides, 2023-2035
12.3.1.8. Antibiotics Market for Tetracyclines, 2023-2035
12.3.1.9. Antibiotics Market for Other Classes, 2023-2035
12.3.2. Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035
12.3.2.1. Antibiotics Market for Bacterial Infections, 2023-2035
12.3.2.2. Antibiotics Market for Dermatological/ Skin Infections, 2023-2035
12.3.2.3. Antibiotics Market for Gastrointestinal Infections, 2023-2035
12.3.2.4. Antibiotics Market for Hematological Infections, 2023-2035
12.3.2.5. Antibiotics Market for Nephrological Infections, 2023-2035
12.3.2.6. Antibiotics Market for Pulmonary Infections, 2023-2035
12.3.2.7. Antibiotics Market for Reproductive Tract Infections, 2023-2035
12.3.2.8. Antibiotics Market for Respiratory Tract Infections, 2023-2035
12.3.2.9. Antibiotics Market for Sexually Transmitted Diseases, 2023-2035
12.3.2.10. Antibiotics Market for Urinary Tract Infections, 2023-2035
12.3.2.11. Antibiotics Market for Other Bacterial Infections, 2023-2035
12.3.3. Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035
12.3.3.1. Antibiotics Market for Monotherapies, 2023-2035
12.3.3.2. Antibiotics Market for Combination Therapies, 2023-2035
12.3.4. Antibiotics Market: Distribution by Route of Administration, 2023 and 2035
12.3.4.1. Antibiotics Market for Intravenous Therapies, 2023-2035
12.3.4.2. Antibiotics Market for Oral Therapies, 2023-2035
12.3.5. Antibiotics Market: Distribution by Geography, 2023 and 2035
12.3.5.1. Antibiotics Market in North America, 2023-2035
12.3.5.2. Antibiotics Market in Europe, 2023-2035
12.3.5.2. Antibiotics Market in Asia-Pacific, 2023-2035
12.3.5.3. Antibiotics Market in Rest of the World, 2023-2035
12.3.6. Sales Forecast: Approved Antibiotics
12.3.6.1. Aemcolo?: Sales Forecast, 2023-2035
12.3.6.2. Arikayce?: Sales Forecast, 2023-2035
12.3.6.3. Baxdela?: Sales Forecast, 2023-2035
12.3.6.4. Dalacin C: Sales Forecast, 2023-2035
12.3.6.5. Dovprela?: Sales Forecast, 2023-2035
12.3.6.6. Emrok: Sales Forecast, 2023-2035
12.3.6.7. Emrok-O: Sales Forecast, 2023-2035
12.3.6.8. Fetroja?: Sales Forecast, 2023-2035
12.3.6.9. Kimyrsa?: Sales Forecast, 2023-2035
12.3.6.10. Lasvic?: Sales Forecast, 2023-2035
12.3.6.11. Nuzyra?: Sales Forecast, 2023-2035
12.3.6.12. Orbactiv?/Tenkasi: Sales Forecast, 2023-2035
12.3.6.13. Ozanex?: Sales Forecast, 2023-2035
12.3.6.14. Quofenix: Sales Forecast, 2023-2035
12.3.6.15. Recarbrio?: Sales Forecast, 2023-2035
12.3.6.16. Seysara?: Sales Forecast, 2023-2035
12.3.6.17. Solosec?: Sales Forecast, 2023-2035
12.3.6.18. Vabomere?: Sales Forecast, 2023-2035
12.3.6.19. Xenleta?: Sales Forecast, 2023-2035
12.3.6.20. XEPI?: Sales Forecast, 2023-2035
12.3.6.21. Xerava?: Sales Forecast, 2023-2035
12.3.6.22. Xydalba?: Sales Forecast, 2023-2035
12.3.6.23. Youxitai: Sales Forecast, 2023-2035
12.3.6.24. Zemdri?: Sales Forecast, 2023-2035
12.3.6.25. Zerbaxa?: Sales Forecast, 2023-2035
12.3.6.26. Zyvoxam?: Sales Forecast, 2023-2035
12.3.7. Sales Forecast: Clinical-stage Antibiotics
12.3.7.1. Cefepime-Taniborbactam: Sales Forecast, 2023-2035
12.3.7.2. CONTEPO?: Sales Forecast, 2023-2035
12.3.7.3. Gepotidacin (GSK2140944): Sales Forecast, 2023-2035
12.3.7.4. MBK-01: Sales Forecast, 2023-2035
12.3.7.5. MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2035
12.3.7.6. Nafithromycin (WCK 4873): Sales Forecast, 2023-2035
12.3.7.7. RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, 2023-2035
12.3.7.8. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2035
12.3.7.9. Ridinilazole (SMT 19969): Sales Forecast, 2023-2035
12.3.7.10. Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2035
12.3.7.11. Tebipenem HBr: Sales Forecast, 2023-2035
12.3.7.12. WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2035
12.3.7.13. WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2035
12.3.7.14. XNW4107 (Funobactam): Sales Forecast, 2023-2035
12.3.7.15. Zabofloxacin: Sales Forecast, 2023-2035
12.3.7.16. Zoliflodacin (ETX0914): Sales Forecast, 2023-2035

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS